In a pre-fillable syringe vehicle where a poorly water-soluble BCS II weak base cannot be dissolved by pH adjustment alone, 2-pyrrolidone is evaluated as a water-miscible aprotic co-solvent at 5–30% v/v in water-for-injection. The co-solvent reduces the dielectric constant of the aqueous vehicle and disrupts hydrogen bonding among water molecules; the solubility gain is pH-dependent, and at 30% v/v the toxicology justification becomes a more significant constraint than the API solubility response. Published formulation data for this exact configuration is limited; bracketed screening is therefore performed with 2-pyrrolidone fractions of 0%, 10%, 20%, and 30% v/v, using the API free-base or salt form selected by purity and counterion content. Compounding is carried out in a 316L stainless-steel vessel under nitrogen overlay at 0.2–0.4 bar; the API is dissolved first in 2-pyrrolidone before slow addition to water-for-injection at 4–8°C to minimize local supersaturation. The bulk solution is mixed with a magnetically coupled impeller at 50–150 rpm for 30–45 min, sampled for pH, density, osmolality, and UV assay, then passed through a 0.22 μm PVDF or PES sterilizing filter. Filling is performed under ISO 5 unidirectional airflow at 0.45 ± 0.05 m/s into pre-sterilized 1–3 mL glass syringes with baked silicone barrels. Terminal sterilization may be used only when degradation kinetics demonstrate acceptable hydrolysis; the lactam ring undergoes acid-catalyzed ring opening to 4-aminobutyric acid at pH ≤4.0 and at elevated temperature, so terminal autoclaving at 121°C for 15 min can raise impurity burdens and shift pH. If terminal sterilization is not feasible, aseptic processing is validated under 21 CFR 211.113. The resulting dosage form is a sterile injectable solution for intravenous or intramuscular administration, supplied as a single-dose pre-filled syringe.

Why Does High-Shear Granulation End-Point Control Drift When 2-Pyrrolidone Enters the Binder Fluid?

High-shear granulation end-point control drifts from water-based values when 2-pyrrolidone is present in the binder fluid at 20% w/w; in a 300 L top-drive high-shear granulator with main impeller tip speed 3–7 m/s and side chopper 1500–3000 rpm, a binder fluid composed of povidone 5% w/w in purified water:2-pyrrolidone 80:20 is sprayed at 8–15% w/w of dry powder mass. Because 2-pyrrolidone has a boiling point of 245°C and remains miscible with water throughout the wet massing phase, it lowers the evaporation rate of the granulating fluid and increases the liquid saturation of the powder bed at the same spray volume. The impeller power-consumption curve therefore reaches its end-point inflection earlier than a water-only binder; on production batches, the shift is 10–25% of the water-based wet-massing time and varies with active pharmaceutical ingredient particle size distribution. The granulation end-point is not defined by fixed time; it is defined by a rising power curve plateau and sampled granule size D50 150–300 μm. The wet mass is discharged through a 4 mm screen into a fluid-bed dryer with inlet air at 50–60°C, dew point −20°C or lower, until loss on drying reaches 1.5–2.5% w/w by USP<731>. Residual 2-pyrrolidone in dried granules is typically 1.0–3.5% w/w of tablet mass when the granulating fluid is applied at 12–14% w/w and contains 20% w/w 2-pyrrolidone; residual amounts above 3.5% w/w can act as a moisture-retaining plasticizer and increase tablet capping tendency at compression force 60–100 N. Milling is carried out through a 0.8–1.6 mm screen; the final blend includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. Tablets are compressed to hardness 60–100 N, disintegration ≤15 min, and compliance is verified by USP<711> dissolution Apparatus 2, USP<905> uniformity of dosage units, and USP<467> residual solvent testing; in-process controls fall under 21 CFR 211.110. The finished product is a film-coated immediate-release tablet.

When a poorly water-soluble API is filled in a hard gelatin capsule, a single hydrophilic vehicle such as PEG 400 can produce precipitation on cooling; 2-pyrrolidone is introduced at 5–15% w/w of total fill mass as a crystallization inhibitor and viscosity modifier in a system containing PEG 400 and propylene glycol. The final fill mass is prepared in a heated jacketed vessel at 45–65°C under vacuum −0.6 to −0.8 bar; the API is dissolved first in 2-pyrrolidone, then diluted with molten or heated PEG 400. Water content of the fill before encapsulation is controlled to NMT 0.5% w/w by Karl Fischer titration according to USP<921>. The liquid fill is injected into size 0 or 1 hard gelatin or HPMC capsules at 40–50°C; band sealing follows at 50–60°C using a LEMS system. Compliance checks include USP<1094> for capsule quality attributes, USP<711> for dissolution, and stability testing under ICH Q1A(R2) and 21 CFR 211.166. Because 2-pyrrolidone is hygroscopic, the filling suite is maintained at 40–50% RH; excursions above 60% RH for more than 4 h can increase shell moisture uptake and produce shell softening or brittleness after drying. The finished product is a liquid-filled hard capsule for oral administration; published data for this specific fill matrix is limited, and bracketed fill formulations at 5%, 10%, and 15% w/w are required to establish dissolution stability over 24 months.

Fluid-Bed Spray Granulation of Oral Suspension Powders Using a Binder System with 2-Pyrrolidone

Top-spray fluid-bed granulation of a reconstitutable oral suspension powder uses an aqueous binder solution containing hypromellose 3% w/w and 2-pyrrolidone at 0.5–1.5% w/w of final dry granule mass. The process is run in a top-spray unit with inlet air temperature 40–55°C, spray rate 5–15 g/min per kg of substrate, and final product temperature 30–35°C. Granules are sized to D50 150–300 μm; water content by USP<921> is held below 2.0% w/w to avoid agglomeration in sachet filling and screen blinding during dry milling. Uniformity of dosage units is verified by USP<905> on the sachet fill; release testing follows ICH Q6A for oral powders; in-process controls are documented under 21 CFR 211.165. The finished product is a single-dose sachet of granules for reconstitution into an oral suspension.

When Modified-Release Multiparticulates Require Drug Layering onto Sugar Spheres with a Polar Aprotic Cosolvent

For modified-release multiparticulate drug layering onto 250–355 μm sugar spheres, a Wurster-bottom spray fluid bed is operated with a solution of API and binder in water:2-pyrrolidone 90:10; the 2-pyrrolidone content in the layered pellet is 0.5–1.0% w/w of coated sphere mass. The fluid bed is operated with inlet air temperature 35–45°C, atomizing air pressure 1.5–3.0 bar, and spray rate calibrated to maintain product temperature 28–32°C. The layered pellets are then coated with a sustained-release polymer system; residual 2-pyrrolidone in the final multiparticulate is monitored by headspace gas chromatography under USP<467>. Dissolution of the finished capsule or compressed tablet is verified by USP<711>; uniformity by USP<905>; specification setting follows ICH Q6A. The finished product is a modified-release multiparticulate capsule or tablet. Operational boundary: avoid increasing 2-pyrrolidone above 10% w/w of layering solution because pellet agglomeration and nozzle clogging increase at product temperature ≥35°C.